Safety is a priority: we monitor patients, and use peptides with established safety records
The internet is full of images that range from genuinely impressive clinical documentation to misleading photography that would make any skin look "transformed" regardless of the product used
Its important to note that while peptides are not FDA-approved, they have been used in research and clinical settings with excellent results
In principle, a woman with both insulin-resistant and GnRH-dysregulated PCOS could benefit from both, though no combined protocol exists in clinical practice yet
Both candidates are designed to move beyond single-pathway GLP-1 therapy, but they take very different routes: CagriSema combines an amylin analog with semaglutide, while Retatrutide compresses GIP, GLP-1, and glucagon agonism into one investigational peptide
Schedule at least three consultations